

Code Updates

The following service(s) previously not covered will be covered with no prior authorization for MGB ACO line of business only:

Code	Description	Effective Date
76981	Ultrasound, elastography; parenchyma (e.g., organ)	04/01/2023
76982	Ultrasound, elastography; first target lesion	04/01/2023
76983	Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)	04/01/2023

The following service(s) will be covered with prior authorization for MGB ACO, Commercial/ASO lines of business when billed with non-BH diagnosis codes:

Code	Description	Effective Date
96130	Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour	01/01/2024
96131	Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)	01/01/2024
96136	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes	01/01/2024
96137	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)	01/01/2024
96138	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes	01/01/2024
96139	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)	01/01/2024

The following service(s) are now covered under the medical benefit no prior authorization required for the Commercial/ASO and MGB ACO lines of business:

Code	Description	Vaccine Name	Effective Date
90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Beyfortus	COMM: 10/01/2023 MH: 10/02/2023
90381	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	Beyfortus	COMM: 10/01/2023 MH: 10/02/2023
90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	Abrysvo	COMM: 10/01/2023 MH: 10/02/2023
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	Arexvy	COMM: 10/01/2023 MH: 10/02/2023

The following service(s) are now covered under the medical benefit no prior authorization required for the Commercial/ASO, MGB ACO, and Medicare Advantage lines of business:

Code	Description	Vaccine Name	Effective Date
90480	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose	N/A	09/11/2023
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Comirnaty	09/11/2023
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Comirnaty	09/11/2023
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Comirnaty	09/11/2023
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	Spikevax	09/11/2023



91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	Spikevax	09/11/2023
-------	--	-----------------	------------

The following Diagnosis code is covered under the preventive medical benefit for Commercial/ASO, MGB ACO lines of business:

Code	Description	Effective Date
Z29.81	Encounter for HIV pre-exposure prophylaxis	10/1/2023

Drug Code Updates

The following drug(s) are now covered under the medical benefit with prior authorization required for the Commercial/ASO lines of business:

Code	Description	Brand Name	Effective Date
No Specific Code	Injection, rozanolixizumab-noli, for subcutaneous	Rystiggo	10/01/2023
No Specific Code	Injection, efgartigimod alfa and hyaluronidase-qvfc, for subcutaneous use	Vyvgart Hytrulo	10/01/2023

The following drug(s) are now covered under the medical benefit no prior authorization required for the Commercial/ASO lines of business:

Code	Description	Brand Name	Effective Date
No Specific Code	Injection, glofitamab-gxbm, for intravenous use	Columvi	10/01/2023

The following drug(s) are now covered under the medical benefit with prior authorization required for the Medicare Advantage lines of business:

Code	Description	Brand Name	Effective Date
No Specific Code	Injection, glofitamab-gxbm, for intravenous use	Columvi	10/01/2023



No Specific Code	Injection, rozanolixizumab-noli, for subcutaneous	Rystiggo	10/01/2023
No Specific Code	Injection, efgartigimod alfa and hyaluronidase-qvfc, for subcutaneous use	Vyvgart Hytrulo	10/01/2023

